Arvinas (ARVN) Q3 2026 Earnings Call Transcript

Arvinas reported $558.9 million in cash, restricted cash and marketable securities at Sept. 30, 2026, with cash runway into the second half of 2028; non-GAAP expenses fell 25% year over year to $53.5 million, while revenue was $0.5 million from Rigel royalties. Management outlined multiple pipeline readouts for 2027, including ARV-027 and ARV-6723, but ARV-102 remains on FDA clinical hold and its planned Phase I-B study is expected to begin in Europe and the U.K. without U.S. patients.

Analysis

ARVN’s near-term setup is a sequence of clinical-optionality events, not a change in current earnings power. The December ARV-393 update may be misread if investors compare its small, early T-cell cohort directly with mature B-cell data from other programs: management says many patients were dosed below predicted efficacious exposure, and durability at higher doses will be limited. The more decision-relevant test is whether exposure, target degradation, tolerability, and responses improve together in the larger 2027 B-cell dataset. A weak December efficacy readout alone would not settle the asset; poor PK/PD or dose-limiting safety would be more damaging.

The portfolio has offsetting binary risks. ARV-027’s healthy-volunteer muscle degradation is a useful pharmacology bridge, but the 50% benchmark is preclinical, not evidence of human functional benefit; rare-disease recruitment and translation to clinical endpoints remain constraints. ARV-102’s European trial path preserves development, while the FDA hold raises execution and geographic-enrollment risk; biomarker movement is not yet validated clinical benefit. ARV-6723’s checkpoint-resistant preclinical models create upside, but human tumor activity is unproven and arrives later. Expense cuts extend optionality, but do not establish improved pipeline productivity. The Rigel royalty is too small, on the disclosed quarter’s evidence, to alter ARVN’s funding profile or materially change RIGL’s investment case. Overall, avoid treating a diversified early-stage pipeline as diversified clinical risk: several programs still depend on translating target engagement into patient benefit.

Key Decisions for Investors

• No aggressive directional position ahead of the December ARV-393 readout without valuation and positioning context. Treat it as a volatility catalyst; assess safety, PK/PD, dose and patient-level exposure before judging the efficacy signal.
• For a conditional ARVN long, prefer waiting for the December data and adding only if target degradation and tolerability support continued dose escalation. The 1–3 month catalyst is interpretation of the ASH dataset; the stronger validation window is the larger, higher-dose B-cell readout targeted for mid-2027. Falsify the thesis on inadequate target degradation, dose-limiting toxicity, or no coherent exposure-response signal.
• Keep ARV-027 and ARV-6723 as watch items rather than underwriting them as near-term value drivers: monitor 2027 human degradation/biomarker results and evidence that these translate into functional or antitumor activity. For ARV-102, track FDA-hold resolution and EU/UK trial initiation; slippage or a failure to connect biomarkers to disease-relevant measures weakens the longer-term case.
• Do not use the disclosed Rigel royalty as a standalone RIGL catalyst. Verify subsequent royalty scale and underlying product sales before assigning meaningful earnings sensitivity; the current disclosed amount does not establish a material consolidated impact.